SCHEDULE: Vanguard Discloses 5.03% Stake in Intellia Therapeutics

Vanguard Capital Management has reported beneficial ownership of 5.03% of Intellia Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, through its affiliates, now beneficially owns 5,945,571 shares of Intellia Therapeutics Inc. common stock.
• This holding represents 5.03% of the total class of securities.
• The filing indicates sole voting power for 861,466 shares and sole dispositive power for 5,945,571 shares.
• The reporting date for this ownership stake is March 31, 2026.
• Vanguard Capital Management is classified as an investment adviser (IA).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the significant stake taken by a major institutional investor like Vanguard, indicating confidence in the company's future prospects.

Positives

• Vanguard's increased stake suggests confidence in Intellia Therapeutics' long-term prospects, potentially attracting further institutional investment.
• Holding over 5% of the class of securities indicates a significant institutional investor presence, which can be viewed positively by the market.

Negatives

• The filing does not contain any negative financial results or operational setbacks for Intellia Therapeutics.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks faced by Intellia Therapeutics. However, any investment carries inherent market risks.
• The nature of Intellia Therapeutics' business in gene editing and therapeutics implies significant research and development risks, regulatory hurdles, and market adoption challenges, though these are not detailed in this specific filing.

Future Outlook

This filing is a snapshot of ownership as of March 31, 2026, and does not contain forward-looking statements or guidance from Intellia Therapeutics itself. Vanguard's future investment decisions are not disclosed.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by a major institutional investor like Vanguard, indicating ownership exceeding 5%, is a significant event for a biotechnology company like Intellia Therapeutics. It signals growing institutional support and can influence market perception and potentially attract further investment, especially in a sector driven by innovation and long-term growth potential.

Stakeholder Impact

• Shareholders: The increased institutional ownership by Vanguard may lead to greater market stability and potentially attract more investors, positively impacting share value.
• Employees: Continued institutional support can bolster confidence in the company's long-term viability and growth, indirectly benefiting employees.
• Creditors: A stable and well-supported company is generally viewed favorably by creditors.

Next Steps

• Vanguard will continue to hold and potentially adjust its stake in Intellia Therapeutics based on its investment strategy.
• Intellia Therapeutics will continue its operations, research, and development activities.

Key Dates

Recommendation

This filing indicates a significant institutional investment by Vanguard, suggesting confidence in Intellia Therapeutics. However, as a 13G filing, it does not provide operational or financial performance details of Intellia itself. Therefore, while positive, it warrants a 'hold' recommendation pending further analysis of Intellia's core business performance and clinical trial progress.

Keywords

Intellia Therapeutics, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Gene Editing, Biotechnology